Pembrolizumab Shows Durable Benefit as Third-Line Treatment of Advanced Small Cell Lung Cancer


“Pembrolizumab demonstrated antitumor activity and induced durable responses in patients with advanced small cell lung cancer who had received two or more previous lines of therapy, according to pooled data from two KEYNOTE trials presented at American Association for Cancer Research Annual Meeting.”

Go to full article published by Healio on April 3, 2019

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.